CHAIRMAN LEVEL |
EXECUTIVE LEVEL |
DIRECTOR LEVEL |
National Stroke Association's mission to reduce the incidence and impact of stroke is enabled by the generous support of our Corporate Alliance Board (CAB), an elite group of industry partners with a mutual interest in stroke awareness and prevention.
Through Corporate Alliance sponsorship and grants, National Stroke Association develops educational programs about all aspects of stroke for the general public, medical professionals, and those touched personally by stroke.
National Stroke Association thanks our CAB members for their dedication to National Stroke Association's mission.
We invite you to join National Stroke Association in our efforts to reduce the incidence and impact of stroke by becoming a member of our Corporate Alliance Board. Distinct levels of sponsorship allow you to select a commitment that is consistent with your goals and resources.
For more information about becoming a CAB partner, please contact any of the following:
|
Sharon Januchowski Jamie Charbonneau |
303-754-0946 303-754-0943 |
View our Corporate Alliance Policy
CHAIRMAN LEVEL |
|
| Allergan, Inc | |
|
Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. |
 |
Bristol-Myers Squibb/Pfizer Inc Partnership |
|
|
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Pfizer Inc is committed to helping people improve their health by discovering and developing medicines, as well as informing consumers and health care providers about our medicines and the medical conditions they treat. Through multiple initiatives, Pfizer aims to ensure access to treatments and educate, empower and motivate consumers to take the necessary steps to lead longer, healthier, happier lives. For more information about Pfizer's patient assistance programs, visit http://www.pfizerhelpfulanswers.com/. |
|
EXECUTIVE LEVEL |
|
| Boehringer Ingelheim Pharmaceuticals | |
|
Boehringer Ingelheim Pharmaceuticals, Inc. discovers, develops and markets innovative and unique medications for the treatment of respiratory, cardiovascular, immunological and central nervous system diseases. BIPI is the maker of Aggrenox (aspirin and extended-release dipyridamole), approved in 1999 as an antiplatelet agent for the treatment of stroke and TIA. |
 |
| Genentech, Inc. | |
|
For over a decade, Genentech has been committed to advancing the treatment of stroke. In 1995, the company's t-PA, Activase® (Alteplase) was approved for reducing disability and improving recovery following acute ischemic stroke. Now, more than 60,000 eligible stroke patients have been treated. Genentech also supports numerous educational programs for healthcare professionals caring for stroke patients. For information on these resources please contact 1-88-TX-STROKE or visit http://www.activase.com/. |
 |
| Medtronic, Inc. | |
|
Medtronic is the global leader in medical technology alleviating pain, restoring health and extending life for millions of people around the world. The company’s product and therapy portfolio includes intrathecal therapy for the management of severe spasticity associated with multiple sclerosis, cerebral palsy, stroke, brain injury, or spinal cord injury. For more information please visit http://www.medtronic.com/ or http://www.yourlifeafterstroke.com/ |
 |
DIRECTOR LEVEL |
|
| ACORDA Therapeutics | |
|
ACORDA Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions. ACORDA markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, ACORDA is developing various clinical stage compounds for the treatment of both acute and chronic spinal cord injury, heart failure, stroke, and a remyelinating monoclonal antibody for the treatment of MS. |
|
| Allsup | |
|
Founded in 1984 by Jim Allsup, a former Social Security field representative, Allsup was the first nationwide, private Social Security disability claims services company. The company built its reputation on the philosophy of “You stay at home. We do the work.”® as well as an expert understanding of the specialized needs of those with disabilities. Allsup has successfully secured disability benefits for more than 200,000 deserving customers. More than 800 employees located at our Belleville, Ill., headquarters and around the country support the needs of our customers. Throughout our history, Allsup has positively influenced how the SSA serves its applicants. We educate our customers on the Social Security disability process, making it less confusing, less intimidating and more convenient for people with disabilities. And we provide the SSA with a well developed claim that allows its staff to issue an informed decision. We are very proud of our 97 percent award rate for applicants who complete the SSDI process with Allsup. In addition, in 2008 Allsup began expanding the True Help® it provides to those with disabilities, providing access to a broad range of financial and healthcare information and services that help our customers live lives that are as financially secure and as healthy as possible. Allsup is proud to support the National Stroke Association Help Line through its Corporate Alliance Board support. |
|
| Avanir Pharmaceuticals, Inc. | |
| AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. We are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir has an investigational drug in development for pseudobulbar affect (PBA), a neurologic condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA occurs in patients with underlying neurologic disease or injury, including stroke. For more information about AVANIR, please visit www.avanir.com. |
|
| H. Lundbeck A/S | |
|
H. Lundbeck A/S is an international Danish pharmaceutical company founded in 1915 and is headquartered in Denmark. Today Lundbeck employs approximately 5,900 people worldwide. As a research based company, every year Lundbeck invests around 20 percent of its revenue in the research and development of new innovative drugs, which will improve the treatment of the millions of people suffering from brain disorders all over the world. In total the company employs around 1,200 highly qualified and specialized employees in our research and development departments. As part of Lundbeck's commitment to improve the health of patients, Greta Lundbeck founded the Lundbeck Institute in 1954 with the aim to increase awareness, and management of CNS related disorders. The Lundbeck International Neuroscience Foundation (LINF) was established with the aim to educate medical professionals in CNS related conditions such as stroke. For more information, please visit: http://lundbeck.com |
 |
| Janssen Pharmaceuticals, Inc. | |
|
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on the people's lives, and we aim to empower people through disease awareness, education and access to quality care. Our research and development strategy focuses on identifying the medical needs, and harnessing the best science in the world, whether from our own laboratories, or through strategic relationships and collaborations. For more information visit http://www.janssen.com/our-companies.html or http://www.afibonetoone.com/ |
 |
| Patterson Medical | |
| Patterson Medical is a leading provider of rehabilitation, assistive and splinting products all over the world. With the industry’s largest catalog and nationwide sales force, Patterson Medical provides Occupational Therapists and Physical Therapists in hospitals, long-term care facilities and clinics the most comprehensive range of products, brand names and services available. With operations in North America, the U.K., Australia and France, Patterson Medical
offers over 30,000 top-name rehabilitation supplies, equipment and assistive
living products. Check out their catalog online at www.pattersonmedical.com
|
 |
Grants and sponsorships enable many of our education programs for healthcare professionals, stroke survivors and caregivers, and the at-risk public. National Stroke Association gratefully acknowledges our 2012 Grants and Sponsorships.
